Jeil Pharmaceutical Co Ltd (271980) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.054x

Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩13.23 Billion ≈ $8.96 Million USD) by net assets (₩243.59 Billion ≈ $165.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Jeil Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Jeil Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 271980 total liabilities for a breakdown of total debt and financial obligations.

Jeil Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
P.C.S. Machine Group Holding Public Company Limited
BK:PCSGH
0.066x
D-Box Technologies Inc.
TO:DBO
0.058x
Digimarc Corporation
NASDAQ:DMRC
0.025x
Chialin Precision Industrial Co Ltd
TWO:3310
-0.028x
SPRINGFIELD PROP. LS-125
F:9MZ
N/A
Resources Connection Inc
F:RCO
-0.038x
Patriot National Bancorp Inc
NASDAQ:PNBK
-0.043x
TTK Healthcare Limited
NSE:TTKHLTCARE
-0.021x

Annual Cash Flow Conversion Efficiency for Jeil Pharmaceutical Co Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of Jeil Pharmaceutical Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Jeil Pharmaceutical Co Ltd market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩219.32 Billion
≈ $148.63 Million
₩3.21 Billion
≈ $2.18 Million
0.015x +146.19%
2023-12-31 ₩157.03 Billion
≈ $106.42 Million
₩-4.98 Billion
≈ $-3.38 Million
-0.032x +67.42%
2022-12-31 ₩155.60 Billion
≈ $105.45 Million
₩-15.15 Billion
≈ $-10.26 Million
-0.097x -185.29%
2021-12-31 ₩167.35 Billion
≈ $113.41 Million
₩19.10 Billion
≈ $12.94 Million
0.114x +203.36%
2020-12-31 ₩172.48 Billion
≈ $116.89 Million
₩-19.05 Billion
≈ $-12.91 Million
-0.110x -164.84%
2019-12-31 ₩170.04 Billion
≈ $115.24 Million
₩28.96 Billion
≈ $19.62 Million
0.170x +46.80%
2018-12-31 ₩184.93 Billion
≈ $125.33 Million
₩21.45 Billion
≈ $14.54 Million
0.116x +590.46%
2017-12-31 ₩177.99 Billion
≈ $120.62 Million
₩-4.21 Billion
≈ $-2.85 Million
-0.024x --

About Jeil Pharmaceutical Co Ltd

KO:271980 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$138.25 Million
₩204.00 Billion KRW
Market Cap Rank
#17938 Global
#875 in Korea
Share Price
₩14000.00
Change (1 day)
-1.82%
52-Week Range
₩12000.00 - ₩17390.00
All Time High
₩104611.38
About

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more